Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Cipla
McKinsey
Cerilliant
AstraZeneca
UBS
Colorcon
Citi

Generated: November 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020630

« Back to Dashboard

NDA 020630 describes ULTIVA, which is a drug marketed by Mylan Institutional and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the ULTIVA profile page.

The generic ingredient in ULTIVA is remifentanil hydrochloride. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the remifentanil hydrochloride profile page.
Summary for 020630
Tradename:ULTIVA
Applicant:Mylan Institutional
Ingredient:remifentanil hydrochloride
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 020630
Mechanism of ActionFull Opioid Agonists
Suppliers and Packaging for NDA: 020630
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630 NDA Mylan Institutional LLC 67457-198 67457-198-03 10 VIAL, GLASS in 1 CARTON (67457-198-03) > 3 mL in 1 VIAL, GLASS (67457-198-00)
ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630 NDA Mylan Institutional LLC 67457-198 67457-198-05 10 VIAL, GLASS in 1 CARTON (67457-198-05) > 5 mL in 1 VIAL, GLASS (67457-198-99)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 1MG BASE/VIAL
Approval Date:Jul 12, 1996TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 10, 2018Product Flag?Substance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 2MG BASE/VIAL
Approval Date:Jul 12, 1996TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 10, 2018Product Flag?Substance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 5MG BASE/VIAL
Approval Date:Jul 12, 1996TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 10, 2018Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 020630

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
US Department of Justice
Moodys
Teva
Dow
Boehringer Ingelheim
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.